A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.

Who can join: the full rules

Inclusion Criteria:

* Participants must voluntarily sign and date an informed consent, approved by an IEC/IRB, prior to the initiation of any Screening or study-specific procedures.
* Adults \>= 18 years of age at the time of the Screening Visit (subjects must also meet the legal age of majority per local law).
* Participants are willing and able to comply with procedures required in the protocol.
* Participants must not be incarcerated and must be freely willing and able to provide informed consent. Examples of subjects unable to freely provide informed consent may include some adults under legal protection measure (e.g., under guardianship/curatorship) or unable to express their consent and select adults under psychiatric care. Investigator's discretion should be applied.
* Participants must fulfil the ACR/EULAR 2013 classification criteria for SSc

Exclusion Criteria:

* Other autoimmune connective tissue diseases, overlap syndromes, or SSc mimics (e.g., scleromyxedema, eosinophilic fasciitis), except scleroderma-associated myopathy and associated Sjögren disease.
* Pulmonary disease with predicted FVC \< 45% at Screening.
* Predicted diffusing capacity for carbon monoxide (DLCO, Hb corrected) \< 25% at Screening.
* History of scleroderma renal crisis within the last 6 months.
* History of severe gastric antral telangiectasias (watermelon stomach).

Study contacts

• Principal investigator: Abbvie INC. — AbbVie
• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Upadacitinib for Severe Alopecia Areata in Children

  This study tests whether upadacitinib can safely help children with severe alopecia areata grow back hair, compared with placebo.

  Recruiting at 14 sites Phase 3 AbbVie · Los Angeles, California and 13 other locations · NCT07772492

• Upadacitinib for Eosinophilic Esophagitis in adults not responding to standard therapy

  This study tests whether upadacitinib, taken with topical corticosteroids, can reduce disease activity in adults with eosinophilic esophagitis who still have symptoms.

  Recruiting Phase 2 University of North Carolina, Chapel Hill · Chapel Hill, North Carolina and 1 other locations · NCT07588568

• Upadacitinib versus infliximab for second-line treatment of acute severe ulcerative colitis

  This trial will see if upadacitinib or infliximab works better to induce remission in adults with acute severe ulcerative colitis who need second-line therapy.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07550673

• Upadacitinib versus corticosteroids for first-line treatment of acute severe ulcerative colitis

  This test will see if upadacitinib works as well as corticosteroids to induce remission in adults with acute severe ulcerative colitis.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07546097

• TNFi plus low-dose upadacitinib versus TNFi dose intensification for Crohn's disease with suboptimal response

  This trial tests whether adding low-dose upadacitinib to a standard TNF blocker helps adults with moderate-to-severe Crohn's disease who haven't responded well to standard-dose infliximab or adalimumab, compared with increasing the TNFi dose.

  Recruiting Phase 4 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07510191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.